Related stocks: Pharmaceutical Preparations
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Related stocks: Pharmaceutical Preparations
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
We are a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. We are developing verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin ( TSLP ), a cytokine which is a clinically validated driver of inflammatory response positioned ups…
The business is unprofitable at the operating level (-5618.82% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 20.4%, still solid. Margins contracted 2337.6pp, which offsets some of the top-line progress.
ROIC dropped from -26.03% to -31.16%, capital efficiency is deteriorating. Negative free cash flow of -$133M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$3M
▲ +20.4% YoY
Net Income (TTM)
-$157M
▼ -128.4% YoY
Op. Margin
-5176.49%
▼ -2337.6pp YoY
ROIC
-37.82%
▼ -5.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$140M
▼ -123.6% YoY
Op. Cash Flow (TTM)
-$140M
▼ -125.2% YoY
Net Debt
-$293M
Net Cash Position
Cash & Equiv.
$295M
Continue Research